author-photo

Eric W Humke

University of Michigan

17

Papers

1109

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 52: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

2021
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.

2020 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (8)
ER pathway activity signature as a biomarker for endocrine agent GDC-9545

2020
Show All
- Source
- Cite
- Save
Citations (0)
The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
ICEBERG: A Novel Inhibitor of Interleukin-1β Generation

2000 Cell
Show All
- Source
- Cite
- Save
Citations (255)
SOLUTION STRUCTURE OF ICEBERG, AN INHIBITOR OF INTERLEUKIN-1BETA GENERATION

2000
Show All
- Source
- Cite
- Save
Citations (0)
Activation of caspases triggered by cytochrome c in vitro 1 This work was supported by the National

1998 FEBS Letters
Show All
- Source
- Cite
- Save
Citations (0)